FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313502514> ?p ?o ?g. }

• W4313502514 endingPage "18" @default.
• W4313502514 startingPage "18" @default.
• W4313502514 abstract "To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared first-line virological response (VR) under tenofovir + lamivudine + dolutegravir (TLD) according to prior exposure to tenofovir + lamivudine + efavirenz (TLE). A facility-based survey was conducted among patients initiating antiretroviral therapy (ART) with TLD (I-TLD) versus those transitioning from TLE to TLD (T-TLD). HIV viral load was performed and unsuppressed participants (VL > 1000 copies/mL) had genotyping performed by Sanger sequencing. Of the 12,093 patients followed, 310 (mean-age: 41 ± 11 years; 52.26% female) complied with study criteria (171 I-TLD vs. 139 T-TLD). The median ART-duration was 14 (12−17) months among I-TLDs versus 28 (24.5−31) months among T-TLDs (15 (11−19) on TLE and 14 (9−15) on TLD), and 83.15% (148/178) were at WHO clinical stages I/II. The viral suppression rate (<1000 copies/mL) was 96.45%, with 97.08% among I-TLDs versus 95.68% among T-TLDs (p = 0.55). VR was similar in I-TLD versus T-TLD at <400 copies/mL (94.15% versus 94.42%) and age, gender, residence, ART-duration, and WHO stages were not associated with VR (p > 0.05). Genotyping was successful for 72.7% (8/11), with no major mutations to integrase inhibitors found. VR is optimal under first-line TLD after 14 months, even among TLE-exposed, thus confirming the effectiveness of transitioning from TLE to TLD in similar settings, supported by strong pharmacological potency and genetic barrier of dolutegravir." @default.
• W4313502514 created "2023-01-06" @default.
• W4313502514 creator A5003964599 @default.
• W4313502514 creator A5004858539 @default.
• W4313502514 creator A5006906812 @default.
• W4313502514 creator A5008306253 @default.
• W4313502514 creator A5013575025 @default.
• W4313502514 creator A5020369127 @default.
• W4313502514 creator A5023984688 @default.
• W4313502514 creator A5024628206 @default.
• W4313502514 creator A5029725075 @default.
• W4313502514 creator A5029881864 @default.
• W4313502514 creator A5030304616 @default.
• W4313502514 creator A5030877404 @default.
• W4313502514 creator A5037945823 @default.
• W4313502514 creator A5050720946 @default.
• W4313502514 creator A5052368236 @default.
• W4313502514 creator A5056820146 @default.
• W4313502514 creator A5063556851 @default.
• W4313502514 creator A5067972537 @default.
• W4313502514 creator A5069733218 @default.
• W4313502514 creator A5073591477 @default.
• W4313502514 creator A5076980268 @default.
• W4313502514 creator A5078010711 @default.
• W4313502514 creator A5078478462 @default.
• W4313502514 creator A5084242627 @default.
• W4313502514 creator A5084589140 @default.
• W4313502514 creator A5085649886 @default.
• W4313502514 creator A5087010496 @default.
• W4313502514 creator A5087278374 @default.
• W4313502514 creator A5088139682 @default.
• W4313502514 date "2022-12-21" @default.
• W4313502514 modified "2023-10-17" @default.
• W4313502514 title "Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model" @default.
• W4313502514 cites W1972061875 @default.
• W4313502514 cites W1984649792 @default.
• W4313502514 cites W2002583799 @default.
• W4313502514 cites W2012607545 @default.
• W4313502514 cites W2043873958 @default.
• W4313502514 cites W2085405111 @default.
• W4313502514 cites W2091460793 @default.
• W4313502514 cites W2109861188 @default.
• W4313502514 cites W2170231953 @default.
• W4313502514 cites W2209222401 @default.
• W4313502514 cites W2278758730 @default.
• W4313502514 cites W2488789925 @default.
• W4313502514 cites W2557649084 @default.
• W4313502514 cites W2614760633 @default.
• W4313502514 cites W2765514580 @default.
• W4313502514 cites W2800677865 @default.
• W4313502514 cites W2925271821 @default.
• W4313502514 cites W2953475125 @default.
• W4313502514 cites W2960510162 @default.
• W4313502514 cites W2973098945 @default.
• W4313502514 cites W2995015948 @default.
• W4313502514 cites W3004533834 @default.
• W4313502514 cites W3026701162 @default.
• W4313502514 cites W3032571821 @default.
• W4313502514 cites W3081112286 @default.
• W4313502514 cites W3087028777 @default.
• W4313502514 cites W3122539841 @default.
• W4313502514 cites W3126054013 @default.
• W4313502514 cites W3128150395 @default.
• W4313502514 cites W3137211483 @default.
• W4313502514 cites W3173951581 @default.
• W4313502514 cites W3209957363 @default.
• W4313502514 cites W4200364111 @default.
• W4313502514 cites W4206043506 @default.
• W4313502514 cites W4225605119 @default.
• W4313502514 cites W4288032966 @default.
• W4313502514 doi "https://doi.org/10.3390/v15010018" @default.
• W4313502514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36680058" @default.
• W4313502514 hasPublicationYear "2022" @default.
• W4313502514 type Work @default.
• W4313502514 citedByCount "1" @default.
• W4313502514 countsByYear W43135025142023 @default.
• W4313502514 crossrefType "journal-article" @default.
• W4313502514 hasAuthorship W4313502514A5003964599 @default.
• W4313502514 hasAuthorship W4313502514A5004858539 @default.
• W4313502514 hasAuthorship W4313502514A5006906812 @default.
• W4313502514 hasAuthorship W4313502514A5008306253 @default.
• W4313502514 hasAuthorship W4313502514A5013575025 @default.
• W4313502514 hasAuthorship W4313502514A5020369127 @default.
• W4313502514 hasAuthorship W4313502514A5023984688 @default.
• W4313502514 hasAuthorship W4313502514A5024628206 @default.
• W4313502514 hasAuthorship W4313502514A5029725075 @default.
• W4313502514 hasAuthorship W4313502514A5029881864 @default.
• W4313502514 hasAuthorship W4313502514A5030304616 @default.
• W4313502514 hasAuthorship W4313502514A5030877404 @default.
• W4313502514 hasAuthorship W4313502514A5037945823 @default.
• W4313502514 hasAuthorship W4313502514A5050720946 @default.
• W4313502514 hasAuthorship W4313502514A5052368236 @default.
• W4313502514 hasAuthorship W4313502514A5056820146 @default.
• W4313502514 hasAuthorship W4313502514A5063556851 @default.
• W4313502514 hasAuthorship W4313502514A5067972537 @default.
• W4313502514 hasAuthorship W4313502514A5069733218 @default.
• W4313502514 hasAuthorship W4313502514A5073591477 @default.
• W4313502514 hasAuthorship W4313502514A5076980268 @default.

• next